A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas

Conditions

Melanoma, skin

Phase 1a/1b

What is the purpose of this trial?

The purpose of this study is to assess the safety and tolerability of escalating doses of TRQ15-01 in patients with relapsed/refractory/metastatic or locally-advanced solid tumors and lymphomas.

  • Trial with
    Torque Therapeutics
  • Start Date
    05/02/2019
  • End Date
    08/31/2021

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Neta Shanwetter Levit

  • Last Updated
    05/06/2019
  • Study HIC
    #2000024303